Artículo:

What do you do when all units are incompatible?
If all red blood cells (RBCs) (and most or all RBCs of a phenotyped red cell panel) are incompatible when tested with a patient's serum/plasma, the results may be due to autoantibody(ies) or alloantibody(ies). In a patient who has not been transfused recently, the differentiation is easy by looking at the result with autologous RBCs. If autologous RBCs are not reacting, then the incompatibilities are due to alloantibody(ies). If the autologous RBCs are incompatible, then an autoantibody alone or an autoantibody plus alloantibody may be present. If the patient has been transfused recently, then the results with autologous RBCs may not have much value and further procedures (e.g., separating transfused “older” RBCs from autologous “younger” RBCs) may be necessary. The autoantibody or alloantibody may react optimally at cold (0-5 °C) or warm (37 °C) temperatures. Table I shows some of the specificities that may be involved when all, or most, RBCs tested are reacting.

### Incompatibility associated with autoantibodies

The autoantibody may be a cold autoagglutinin, or reacting at 37 °C [usually by indirect antiglobulin test (IAT)]. If the patient has a 37 °C reacting autoantibody, the direct antiglobulin test (DAT) should be positive.

The first question to answer is: Does the patient's serum contain autoantibody alone, autoantibody + alloantibody, or alloantibody alone? If the patient has autoimmune hemolytic anemia (AIHA), one should never assume that incompatibilities are only due to autoantibody. It is very important to answer the question above as blood incompatible with the autoantibody may not survive any better than the patient's own RBCs, but will not usually cause an overt hemolytic transfusion reaction. In contrast, an alloantibody masked by the autoantibody may cause a severe reaction. We have found that 40% of our AIHA,

<table>
<thead>
<tr>
<th>Table I</th>
<th>Specificities of antibodies reacting with most or all RBCs tested</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Auto</strong></td>
<td>I, i, IH, H, Pr, Gd, Sa, Fl, Ju, Me, Lud, Rx, P, Vel</td>
</tr>
<tr>
<td>Cold antibodies</td>
<td>En*, Vel, Sd*, P, PP1P*, M+Le*, P1+Le*, M+P1</td>
</tr>
<tr>
<td>Warm antibodies</td>
<td>“Rh”, LW, En*, Ge, Kp*, K13, Jk3, U, Sc1, Sc3, Vel, I*, AnWj, Rx</td>
</tr>
<tr>
<td><strong>Allo</strong></td>
<td>Hr*, Hr, hr, hr*, Rh29, 38, 39, LW, Fy3; k, Kp* Ku, Js, KL, K11-16, K18-20, K22, Jk3; U; En; Wf; Lu; Lu3-8; Lu11-13; AnWj; Di; Yt; Sc1; Sc3; Co; Co3; In; Vel; Ge; Lan; At; Gy; Hy; Cr; Jr; Ch; Rg; Cs; Yk; Kn; McC; JMH; Er</td>
</tr>
</tbody>
</table>

---

**Key words**
- Immunohematology
- Red cell transfusion
- Immunohematology
- Red blood cell transfusion
associated with 37 °C-reactive autoantibodies, have alloantibody masked by autoantibody.\textsuperscript{1,8} To provide blood for transfusion to such patients we suggest that one of the approaches shown in Table II is used before issuing blood for transfusion.

### Approaches using dilutions of patients’ serum

Because the warm autoantibody is being adsorbed continually by the patient’s RBCs, there is likely to be less autoantibody left in the serum than if an alloantibody is present. If dilutions of the patient’s serum are tested, sometimes the stronger alloantibody becomes obvious.

We titrate the patient’s serum against a pool of antibody detection RBCs and select a dilution that is yielding a 1+ reaction.\textsuperscript{1} This dilution is tested against a panel of red cells to determine specificity. Sometimes a serum that was originally reacting 3-4+ with all panel red cells will now react with only some of the panel [e.g., E+, K+, or Jk(a+) red cells]. Table III shows a result where an alloanti-c was masked by autoantibody. Oyen et al\textsuperscript{7} described a modification of this using a single dilution (1 in 5) of the patient's serum. Leger and Garratty\textsuperscript{2} compared this approach with adsorption using ZZAP-treated allogeneic RBCs and found that 27% of alloantibodies of potential clinical significance were detected by adsorption but not by the 1 in 5 dilution approach. Nevertheless, the approach is useful if adsorptions cannot be performed or is too time-consuming for a particular patient’s clinical need for transfusion.

### Dealing with cold autoantibodies

Most cold autoantibodies are of low titer and thermal amplitude and if interfering with pretransfusion testing, can be easily autoadsorbed by incubating the patient's RBCs and serum plasma at 0-5 °C. The whole blood sample can be incubated, or for more efficiency, the patient’s RBCs should be enzyme-treated before incubating with the patient’s serum/plasma.\textsuperscript{3}

Powerful high titer, high thermal amplitude cold autoantibodies (e.g., those associated with AIHA) are much more difficult to deal with. Autoadsorptions with enzyme-treated RBCs will help but many adsorptions may be needed to adsorb all or even most of the autoantibody.

### Adsorption with autologous or allogeneic RBCs

Adsorption with autologous RBCs is the best approach in a patient who has not been transfused recently.\textsuperscript{1} The patient's RBCs are cleared of autoantibody, to expose autoantigens that will adsorb more autoantibody but not alloantibody from the patient's serum. The antibody can be cleared by 56 °C heat elution, EDTA glycine acid elution, or ZZAP reagent.\textsuperscript{1,6} If the first two methods are used, the patient's RBCs are then enzyme-treated; ZZAP contains enzyme so the second step is not necessary. The treated RBCs are then used to adsorb autoantibody from the patient's serum and the serum tested for alloantibody (e.g., against antibody detection RBCs). As a rough guide: if the original indirect antiglobulin test (IAT) was 1+, 2+, 3-4+, then 1, 2, or ≥ 3 adsorptions respectively are usually necessary.\textsuperscript{1} If the patient has been transfused within the last 3 months, then the autoadsorption needs to be performed using allogeneic RBCs.\textsuperscript{1} A single phenotype can be used if it matches the patient’s phenotype. If this is not possible, then we recommend three phenotypes, rr, R1R1, and R2R2 that cover Kidd, Kell, and Ss. If ZZAP is used, then only Jka and Jkb need to be covered (i.e., ZZAP destroys all relevant antigens except Kidd –see Table III). We prefer using ZZAP, as it is a one-step procedure, to elute antibody and destroy many antigens thus stopping adsorption of most alloantibodies except those of the Kidd system.

### Table II

Detection of alloantibodies in the presence of warm autoantibodies

<table>
<thead>
<tr>
<th>Warm autoadsorption</th>
<th>Adsorptions with allogeneic RBCs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>enzyme-treated RBCs</td>
</tr>
<tr>
<td></td>
<td>ZZAP-treated RBCs</td>
</tr>
<tr>
<td></td>
<td>in presence of PEG</td>
</tr>
</tbody>
</table>

Dilution of patient’s serum
Obtaining donor blood for patients with antibodies to high frequency antigens

Screening random units is not usually productive but can be made more efficient by testing only RBCs from appropriate ethnic groups (see Table V). An effort to obtain siblings for typing is important; there is a much better chance of finding a compatible donor among siblings. Donors may have to be obtained from National or International Blood Donor Registries, but this is time-consuming and expensive. Sometimes blood incompatible with an antibody to high frequency antigens can be transfused with no clinical ill effects. For instance, some anti-Yta, Ge, Lan, Lutheran, Era do not cause hemolytic transfusion reactions.8

Determining clinical significance of antibodies to high frequency antigens

Thermal amplitude and specificity: The first pieces of useful information are the thermal amplitude and specificity of the antibody. If antibodies are not reactive at 37 °C [by any test (e.g., antiglobulin test)], they have no potential to be clinically significant and incompatible blood can be transfused. Table V shows the relationship of specificity based on published data.

Table III
Results of dilution technique to show the presence of alloanti-e masked by autoantibody

<table>
<thead>
<tr>
<th>Dilutions of patient's serum</th>
<th>2</th>
<th>4</th>
<th>8</th>
<th>16</th>
<th>32</th>
<th>64</th>
<th>128</th>
<th>256</th>
<th>512</th>
<th>1024</th>
</tr>
</thead>
<tbody>
<tr>
<td>IAT on screening cells (pooled)</td>
<td>3+</td>
<td>3+</td>
<td>3+</td>
<td>2+</td>
<td>2+</td>
<td>1+</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Panel of group O cells

<table>
<thead>
<tr>
<th></th>
<th>rr</th>
<th>rr</th>
<th>r'r</th>
<th>R1R</th>
<th>R1R</th>
<th>R2R</th>
<th>R2R</th>
<th>R2R</th>
</tr>
</thead>
<tbody>
<tr>
<td>Undiluted serum serum diluted</td>
<td>3+</td>
<td>3+</td>
<td>3+</td>
<td>3+</td>
<td>3+</td>
<td>3+</td>
<td>3+</td>
<td>3+</td>
</tr>
<tr>
<td>1 in 64</td>
<td>1+</td>
<td>1+</td>
<td>0</td>
<td>0</td>
<td>1+</td>
<td>1+</td>
<td>1+</td>
<td>1+</td>
</tr>
</tbody>
</table>

IAT = indirect antiglobulin test
Red cell survival using 51Cr-labeled red cells:
The International Committee for Standardization in Hematology published recommendations for a compatibility test using 51Cr-labeled red cells. They suggested using only 0.5 ml of the incompatible 51Cr-labeled red cells. Their interpretation was as follows: "In cases of urgency or when there is great difficulty in finding completely compatible RBCs, donor RBCs may be transfused with minimal hazard when, following a test with 0.5 mL of donor RBCs the amount of radioactivity in the plasma, both at 10 and 60 minutes, does not correspond to more than 3% of the radioactivity injected and when the RBC survival at 60 minutes is not less than 70%.

Functional cellular assays: As the 51Cr approach is not generally available, some investigators developed an in vitro equivalent using various in vitro cellular assays, utilizing monocytes/macrophages, to mimic the reticuloendothelial system. These were: 1) the antibody-dependent cell-mediated cytotoxicity assay (ADCC); 2) the monocyte monolayer assay (MMA); 3) the chemiluminescent test (CLT).

We have used the MMA successfully for about 20 years to help make decisions on transfusing incompatible RBCs. The major problem for these assays is that the definition of "clinical significance" varies. To the more conservative, it means that the transfused incompatible RBCs should have normal survival. Some are satisfied if the patient has no clinical or laboratory signs of a reaction, and the less conservative are satisfied if the patient has no clinical signs of a reaction (e.g., they are not concerned with an increased bilirubin, suggesting abnormal red cell survival despite no clinical signs). The latter is
more acceptable if the patient is hematologically normal (e.g., surgery patient) rather than a hematology patient where optimal survival of transfused RBCs is important. An example of a successful transfusion of RBCs incompatible with anti-Dib, published by Leger and Garratty, illustrated an example in a surgical patient.

“In vivo” compatibility test

A commonly used method is to give a test dose of 5-10 mL of incompatible RBCs slowly and then draw an anticoagulated sample after 10-60 mins and inspect the plasma for hemolysis. This is a very poor approach and can give physicians a false sense of security. The method will only detect acute complement-mediated destruction of red cells as occurs with ABO incompatible blood. Most antibodies destroy RBCs extravascularly in the spleen and liver and do not cause hemoglobinemia (especially of small quantities of blood). Thus, most antibodies to high frequency antigens and even powerful Rh, Kidd, Kell, Duffy antibodies would not appear to be clinically significant using this procedure. Only ABO and rare powerful complement activating antibodies such as examples of anti-Vel, -PP1Pk might give a positive result with this approach. The main disadvantage is that physicians may think that a negative result indicates that it is safe to transfuse the incompatible blood and a severe hemolytic transfusion reaction will not could occur; this is not true!

References